AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$KYMR

Kymera Therapeutics Q3 Earnings Call Highlights

Kymera Therapeutics reported Q3 results, highlighting 98% inhibition of TLR7/8-stimulated interferon-beta levels and positive phase I data for KT-579. The company plans a phase Ib lupus study (LUMORA) in early 2027. KT-621 is expected to show atopic dermatitis efficacy comparable to dupilumab. Q3 R&D expenses were $128.5M, with cash position of $1.6B providing runway into 2029.

Original reporting
finance.yahoo.com
Published Oct 29, 2026, 6:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 6:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Kymera Therapeutics Q3 Earnings Call Highlights — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$KYMRNeutralMed
01

Why it matters

The earnings release adds new financial metrics and pipeline milestones, offering fresh data for valuation models.

02

Market read

New earnings and pipeline data provide actionable insight for biotech investors and may affect KYMR's short‑term price trajectory.

03

What to watch

Potential future collaborations with Sanofi and Gilead are not reflected in current revenue but could unlock value.

Relevance 7/10Novelty 7/10Timing: after-hours

Background

Kymera Therapeutics (NASDAQ:KYMR) provided its Q3 financial results and detailed updates on its lead programs KT-579, KT-621, and collaborations with Sanofi and Gilead.

Company-level read

Ticker impact

$KYMRNeutralHigh confidence
Context

Q3 earnings call disclosed R&D expense of $128.5M, cash $1.6B and pipeline updates including phase Ib lupus study and atopic dermatitis program.

Expected impact

likely modest downside pressure as investors price in cash burn and lack of near‑term revenue

Evidence & confidence

The disclosed financials are new primary data; biotech investors typically react to cash burn and pipeline milestones.

Market effects

Sector

Highlights ongoing investment in protein degradation biotech space, may influence peer valuations.

Regional

US biotech sector may see slight pullback pending further guidance.

Global

Limited to investors tracking clinical-stage biotech pipelines.

Counterpoint

What could challenge this read

Despite cash burn, the sizable cash runway to 2029 and upcoming lupus trial could justify a buy‑on‑dip stance.

Key entities

  • company
    Kymera Therapeutics

    Clinical-stage biotech focused on targeted protein degradation.

  • partner
    Sanofi

    Collaborator on IRAK4 degrader program.

  • partner
    Gilead

    Collaborator on CDK2 molecular glue program.

Read at source← All news

StoryKymera Therapeutics posts $132 million Q3 loss, zero revenue and unveils strong Phase 1 data for IRF5 degrader KT‑579

Also covered by

3 outlets

Related articles

$KYMRMed

Kymera (KYMR) Q3 2026 Earnings Call Transcript

Kymera (KYMR) reported Q3 2026 earnings, highlighting progress in its pipeline, including Phase IIb data for KT-621 in atopic dermatitis (AD) expected by year-end. The BROADEN 2 study's placebo-controlled portion is complete, with 98% of eligible patients enrolling in the open-label extension. The company also discussed market research indicating a demand for safe, effective oral treatments for AD.

finance.yahoo.com
$KYMRMedAI 8/10

Kymera Q3 2026 slides: IRF5 degrader shows 90%+ target engagement

Kymera Therapeutics (KYMR) reported Q3 2026 results, missing earnings but showing 90%+ target engagement for its IRF5 degrader KT-579. The stock rose 3.46% premarket. The company reported a net loss of $132M, up from $82.2M YoY, with R&D expenses increasing 73%. Kymera has $1.6B in cash, providing a runway into 2029. KT-579 showed promising Phase 1 data, with significant biomarker reductions and a favorable safety profile.

investing.com
$KYMRHigh

Kymera Therapeutics 3Q 2026: Revenue $0 Net loss $132M, EPS $(1.32) — 10-Q Summary

Kymera Therapeutics reported 3Q 2026 revenue of $0, down from $2.8M a year earlier, and a net loss of $132M, or $(1.32) per share, compared to a net loss of $82.2M, or $(0.94) per share, in the prior-year quarter. The company's collaboration revenue for the nine months increased to $99.4M, driven by partnerships with Gilead and Sanofi. Research and development spending rose 49%, primarily due to expanded program work and personnel investments.

tradingview.com
$KYMRHighAI 8/10

Kymera reports phase 1 data for KT-579, plans lupus trial

Kymera Therapeutics (KYMR) reported phase 1 trial results for KT-579, showing significant IRF5 degradation and biomarker reductions. The company plans a phase 1b lupus trial in 2027. Q3 2026 net loss was $132.0M, up from $82.2M in 2025, with R&D expenses increasing. Cash reserves are $1.6B, expected to last into 2029. Updates on other clinical trials were also provided.

investing.com
$KYMRHighAI 8/10

Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial

Kymera Therapeutics, Inc. (KYMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial KT-579 (IRF5) Phase 1 healthy volunteer data demonstrated deep, sustained IRF5 degradation, robust modulation of disease-re

SEC EDGAR 8-K